Spots Global Cancer Trial Database for biologic
Every month we try and update this database with for biologic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease | NCT02499783 | Crohn's Disease | adalimumab placebo | 18 Years - 70 Years | AbbVie | |
| Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) | NCT01374971 | Rheumatoid Arth... | Certolizumab Pe... Arthroscopic sy... | 18 Years - | Arthritis Treatment Center, Maryland | |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | NCT02196701 | Psoriasis | Adalimumab Methotrexate | 18 Years - 99 Years | AbbVie | |
| Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | NCT01211262 | Malignant Melan... | IMCgp100 | 18 Years - | Immunocore Ltd | |
| PROvenge Treatment and Early Cancer Treatment | NCT00779402 | Prostate Cancer | Control Sipuleucel-T | 18 Years - 80 Years | Dendreon | |
| Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) | NCT01374971 | Rheumatoid Arth... | Certolizumab Pe... Arthroscopic sy... | 18 Years - | Arthritis Treatment Center, Maryland | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono | |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | NCT02196701 | Psoriasis | Adalimumab Methotrexate | 18 Years - 99 Years | AbbVie | |
| Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis | NCT01078571 | Rheumatoid Arth... | adalimumab (HUM... | 18 Years - | Abbott | |
| Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study | NCT02196701 | Psoriasis | Adalimumab Methotrexate | 18 Years - 99 Years | AbbVie | |
| Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies | NCT05818020 | Biologic | 18 Years - | National Cancer Institute, Naples | ||
| Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma | NCT00815607 | Melanoma | INXN-1001 INXN-3001 | 18 Years - 75 Years | Alaunos Therapeutics | |
| Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis | NCT01078571 | Rheumatoid Arth... | adalimumab (HUM... | 18 Years - | Abbott | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
